Sofgen Pharma S.A.'s net income is $40M, below the Healthcare sector average of $1.5T.
Get informed when a big investor buys or sells
+ FollowAs of Dec 2023
Trailing 12 months ending Dec 2023
Loading...
Loading...
As of the most recent data (December 2023), PROCF shows a net income of $40M. That compares with $43M in the prior-year period — down 5.2% year over year. That is below the Healthcare sector average of $1.5T. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, PROCF's net income is now $40M (was $43M) — a 5.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Sofgen Pharma S.A. is outperforming or lagging.
The Healthcare sector average net income is about $1.5T. Sofgen Pharma S.A. is at $40M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how PROCF stacks up against individual peers as well.
Tracking PROCF's net income over time shows whether Sofgen Pharma S.A. is scaling, shrinking, or reshaping that part of the business. The current reading is $40M That compares with $43M in the prior-year period — down 5.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net income page, Stockcircle has Sofgen Pharma S.A.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $40M) with ownership activity and broader fundamentals.